Research Varying efficacy of intermittent preventive treatment for malaria in infants in two similar trials : public health implications
C. Menéndez,D. Schellenberg,E. Macete,P. Aide,E. Kahigwa,S. Sanz,J. Aponte,J. Sacarlal,H. Mshinda,M. Tanner,P. Alonso
Abstract:Background: Intermittent preventive treatment (IPTi) with sulphadoxine-pyrimethamine (SP) in infants resulted in different estimates of clinical malaria protection in two trials that used the same protocol in Ifakara, Tanzania, and Manhiça, Mozambique. Understanding the reasons for the discrepant results will help to elucidate the action mechanism of this intervention, which is essential for rational policy formulation. Methods: A comparative analysis of two IPTi trials that used the same study design, follow-up, intervention, procedures and assessment of outcomes, in Tanzania and Mozambique was undertaken. Children were randomised to receive either SP or placebo administered 3 times alongside routine vaccinations delivered through the Expanded Program on Immunisation (EPI). Characteristics of the two areas and efficacy on clinical malaria after each dose were compared. Results: The most relevant difference was in ITN's use ; 68% in Ifakara and zero in Manhiça. In Ifakara, IPTi was associated with a 53% (95% CI 14.0; 74.1) reduction in the risk of clinical malaria between the second and the third dose; during the same period there was no significant effect in Manhiça. Similarly, protection against malaria episodes was maintained in Ifakara during 6 months after dose 3, but no effect of IPTi was observed in Manhiça. Conclusion: The high ITN coverage in Ifakara is the most likely explanation for the difference in IPTi efficacy on clinical malaria. Combination of IPTi and ITNs may be the most cost-effective tool for malaria control currently available, and needs to be explored in current and future studies. Trial Registration: Manhiça study registration number: NCT00209795 Ifakara study registration number: NCT88523834 Published: 26 September 2007 Malaria Journal 2007, 6:132 doi:10.1186/1475-2875-6-132 Received: 23 May 2007 Accepted: 26 September 2007 This article is available from: http://www.malariajournal.com/content/6/1/132 © 2007 Menendez et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Malaria Journal 2007, 6:132 http://www.malariajournal.com/content/6/1/132 Page 2 of 8 (page number not for citation purposes) Introduction Despite increased attention to malaria control by donors, researchers, clinicians, and communities, malaria continues to exact an intolerable toll, particularly in sub-Saharan Africa. The development of new tools such as combination of drug therapies and insecticide treated nets (ITNs) have offered hope, but their impact has been limited by low implementation and logistical and financial constraints. No single tool currently exists that can drastically reduce the malaria burden. Given this reality, and while awaiting new technologies, the malaria community must reexamine available data and interventions to look for creative and synergistic control strategies. It is well documented and accepted that the burden of malaria falls greatly on young children and infants [1]. Even in low/moderate malaria transmission settings, where older children suffer the most malaria episodes, infants have the highest fatality rate [2]. Finding costeffective and affordable approaches to deliver malaria control interventions to infants is a public heath priority, especially since adequate control may be followed by important reductions in mortality for infants as well as young children [3]. The Expanded Program on Immunization (EPI) is the only available scheme that involves regular contact between the population at risk and the health system, even in places with very limited access to services. The intermittent preventive treatment in infants (IPTi) consists of administering a treatment dose of an antimalarial drug at predetermined intervals regardless of the presence of parasitaemia or symptoms. Through the EPI, it has the potential to become a cost-effective strategy. IPTi with sulphadoxine-pyrimethamine (SP) has been shown to significantly reduce malaria episodes in randomized trials carried out in Tanzania, and more recently in Ghana and Mozambique [4-6]. The effect of one treatment dose of SP can last as long as 60 days [7]. Thus, the administration of SP coinciding with immunizations through the EPI scheme could provide a period of suppressive prophylaxis that retains some beneficial effects of regular chemoprophylaxis without compromising the development of malaria immunity [8]. Despite the positive results for efficacy and safety, the determinants and underlying protection mechanisms of IPTi are not yet clear. The analysis of differences between clinical trials that use similar designs could provide insight into the potential determinants and possible underlying protection mechanisms, as well as facilitate planning for future policy recommendations. We had the unique opportunity to compare two very similar IPTi trials in two malaria endemic countries in Eastern and Southern Africa. We present results from a comparative analysis of the protective efficacy of IPTi, and examine the factors that may explain the different protection levels achieved [4,6]. The goal is that this information will help garner future research and guide decision making about the most appropriate role of IPTI in malaria control. Methods Study area and population The Tanzanian study was based in Ifakara town, Kilombero District, in rural Tanzania and is described in detail elsewhere [9]. Malaria transmission is perennial with two rainy seasons and a cool, dry season from July to September. Plasmodium falciparum malaria transmission has been intense in the area. The estimated mean annual entomological inoculation rate (EIR) was 300 bites/person/year in the late 1980's and early 1990's in villages surrounding Ifakara town [10]. However, in the last years, malaria transmission in the semi-urban area of Ifakara decreased [2,9] to an overall EIR of 29 infective bites per person per year [11]. Anopheles gambiae, and to a lesser extent Anopheles funestus, are the main vectors. The Ifakara population was estimated to be 55.000 people. In Ifakara, SP was not associated with any late treatment failures, had a in vivo parasitological sensitivity of 69% at day 14 [12], and was the nationally recommended first line treatment for malaria during the study duration. Compliance to routine EPI vaccinations was high; 92% of children received three doses of DTP/OPV and 80% received measles. HIV seroprevalence at antenatal visits was 6.7% in 1998 [13], The use of insecticide treated nets (ITNs) was about 70%. The prevalence of haemoglobin AS genotype in the study children was 12% [4]. In Mozambique the trial was conducted in Manhiça town, Manhiça District, in southern Mozambique. The characteristics of the area have been described in detail elsewhere [14]. The climate is subtropical with a warm and rainy season from November to April, and a cool and dry season during the rest of the year. Perennial malaria transmission with marked seasonality is mostly due to P. falciparum. Anopheles funestus is the main vector and the EIR for 2002 was 38. The population under demographic surveillance was about 70.000 people. During the Mozambique study, first line treatment of uncomplicated malaria changed from chloroquine to amodiaquine plus SP Most recent data from 2001 on the efficacy of SP in this area showed a combined therapeutic efficacy rate of 83% of children treated, with an in vivo parasitological sensitivity of 78.6% at day 14 [15]. Compliance with EPI vaccines was very high, more than 95% of children received all three doses of DTP/polio/Hepatitis B and more than 85% received measles. HIV seroprevalence in antenatal women was 19% in 2003, (Berenguera et al submitted) and ITN use was zero; only 15% of children Malaria Journal 2007, 6:132 http://www.malariajournal.com/content/6/1/132 Page 3 of 8 (page number not for citation purposes) used non-treated nets [6]. No individuals homozygous for sickle cell or carriers have been found in the area through community and hospital based surveys (Menendez unpublished data). Study design Detailed descriptions of the Ifakara [4] and Manhica trials are provided elsewhere [6]. Briefly, in Ifakara infants were recruited at the MCH clinic immediately after receiving dose 2 of DTP/OPV between August 1999 and April 2000. IPTi was given at ages 2, 3, and 9 months alongside routine EPI vaccinations (Figure 1a). In Manhiça, children were recruited from those attending the EPI clinic to receive dose 2 of DTP/OPV/Hep B between September 2002 and February 2004 (Figure 1b). Identical randomization, blinding, treatment concealment and allocation procedures and inclusion and exclusion criteria were followed in each study. Tablets of SP and placebo (consisting of lactose and maize starch) were identical in shape and color and stored in bottles labeled only with a single treatment identification letter by investigators not involved in the studies. Placebo and SP tablets were provided by the same manufacturer (Hoffman La Roche, Basel, Switzerland). Doses of SP/placebo were administered by a health assistant according to body weight (< 5 kg-1/4 tablet, 5– 10 kg-1/2 tablet, > 10 kg-1 tablet), crushed and mixed with water on a tablespoon. Follow-up Assessment of outcomes was similar in both studies. Comparable round-the-clock hospital-based clinical surveillance systems were operating in both sites; at each consultation a detailed standardized questionnaire was completed to document signs and symptoms [16,17]. Blood films were prepared for malaria parasite examination, and the packed cell volume (PCV) was measured if there was a history of fever in the preceding 24 hrs, the axillary temperature was ≥ 37.5°C or the child appeared pale. In Ifakara a previous study showed that prophylac